Johnson & Johnson (NYSE: JNJ) reported that its first-quarter 2020 earnings and revenue came in above the analysts’ expectations citing product sales as well as lower costs and expenses. Region-wise, sales were better in the US than international. The Consumer and Pharmaceutical segments experienced solid high-single-digit growths despite declines in the Medical Devices segment.
The company is mobilizing its resources in the fight against the COVID-19 pandemic. The impact of COVID-19 has been included in the guidance. The reported sales outlook for fiscal 2020 was lowered to $77.5-80.5 billion from $85.4-86.2 billion. Adjusted earnings guidance was reduced to $7.50-7.90 from $8.95-9.10.
Biogen (NASDAQ: BIIB) reported third-quarter 2021 financial results before the regular market hours on Wednesday. The company reported Q3 revenue of $2.78 billion, down 18% year-over-year and higher than the
Verizon (NYSE: VZ) reported Third-quarter 2021 financial results before the regular trading hours on Wednesday. The telecommunications giant reported Q3 revenue of $32.9 billion, up 4.3% year-over-year and above the
Philip Morris International Inc. (NYSE: PM) reported Third-quarter 2021 earnings results today. Net revenues increased 9% year-over-year to $8.1 billion. The reported net income amounted to $2.42 billion compared to